Research graph
References from Neoadjuvant Dual Immunotherapy in <scp>T4</scp> Locally Advanced Deficient Mismatch Repair Gastric or Esophagogastric Junction ( <scp>EGJ</scp> ) Adenocarcinoma. Local targets link to admitted publications; unresolved targets remain external evidence.
Global Burden of Oesophageal and Gastric Cancer by Histology and Subsite in 2018
10.1136/gutjnl-2020-321600 · 2020 · External reference
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 · External reference
Prevalence and Prognosis of Microsatellite Instability in Oesogastric Adenocarcinoma, NORDICAP 16‐01
10.1016/j.clinre.2021.101691 · 2021 · External reference
Individual Patient Data Meta‐Analysis of the Value of Microsatellite Instability as a Biomarker in Gastric Cancer
10.1200/jco.19.01124 · 2019 · External reference
Microsatellite Instability and Programmed Cell Death‐Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled Study
10.1097/sla.0000000000002803 · 2019 · External reference
Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial
10.1001/jamaoncol.2016.6762 · 2017 · External reference
Perioperative Chemotherapy for Gastric Cancer Patients With Microsatellite Instability or Deficient Mismatch Repair: A Systematic Review and Meta‐Analysis
10.1002/cncr.35831 · 2025 · External reference
Adjuvant Chemotherapy for Gastric Cancer Patients With Mismatch Repair Deficiency or Microsatellite Instability: Systematic Review and Meta‐Analysis
10.1245/s10434-021-11050-6 · 2022 · External reference
Is Microsatellite Instability a Prognostic Marker in Gastric Cancer? A Systematic Review With Meta‐Analysis
10.1002/jso.23618 · 2014 · External reference
Phase II Study (NO LIMIT, WJOG13320G) of First‐Line Nivolumab Plus Low‐Dose Ipilimumab for Microsatellite Instability‐High Advanced Gastric or Esophagogastric Junction Cancer
10.1200/jco-24-02463 · 2025 · External reference
Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability‐High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE‐059, KEYNOTE‐061, and KEYNOTE‐062 Clinical Trials
10.1001/jamaoncol.2021.0275 · 2021 · External reference
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline
10.1200/jco.22.02331 · 2023 · External reference
Outcomes and a Prognostic Classifier in Patients With Microsatellite Instability‐High Metastatic Gastric Cancer Receiving PD‐1 Blockade
10.1136/jitc-2023-007104 · 2023 · External reference
Efficacy and Safety of Neoadjuvant Toripalimab Plus Chemotherapy in Localized Deficient Mismatch Repair/Microsatellite Instability‐High Gastric or Esophagogastric Junction Adenocarcinoma (NICE): A Multicentre, Single‐Arm, Exploratory Phase 2 Study
10.1016/j.eclinm.2025.103421 · 2025 · External reference
Neoadjuvant CTLA‐4/PD‐(L)1 Blockade Versus Surgery +/− Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability‐High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis
10.1200/jco-25-00447 · 2025 · External reference
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF‐s633 Trial
10.1200/jco.23.00975 · 2024 · External reference
Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability‐High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study
10.1200/jco.22.00686 · 2023 · External reference
Tremelimumab and Durvalumab as Neoadjuvant or Non‐Operative Management Strategy of Patients With Microsatellite Instability‐High Resectable Gastric or Gastroesophageal Junction Adenocarcinoma: The INFINITY Study by GONO
10.1016/j.annonc.2024.11.016 · 2025 · External reference
TremelImumab and Durvalumab Combination for the Non‐OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)‐High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single‐Arm, Multi‐Cohort, Phase II INFINITY Study
10.3390/cancers13112839 · 2021 · External reference
The Association Between Clinician‐Based Common Terminology Criteria for Adverse Events (CTCAE) and Patient‐Reported Outcomes (PRO): A Systematic Review
10.1007/s00520-016-3297-9 · 2016 · External reference
Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey
10.1097/01.sla.0000133083.54934.ae · 2004 · External reference
Spatial Interactions of Immune Cells as Potential Predictors to Efficacy of Toripalimab Plus Chemotherapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: A Phase Ib/II Trial
10.1038/s41392-024-02031-8 · 2024 · External reference
First‐Line Nivolumab Plus Chemotherapy Versus Chemotherapy Alone for Advanced Gastric, Gastro‐Oesophageal Junction, and Oesophageal Adenocarcinoma (CheckMate 649): A Randomised, Open‐Label, Phase 3 Trial
10.1016/s0140-6736(21)00797-2 · 2021 · External reference
First‐Line Nivolumab Plus Chemotherapy vs Chemotherapy in Patients With Advanced Gastric, Gastroesophageal Junction and Esophageal Adenocarcinoma: CheckMate 649 Chinese Subgroup Analysis
10.1002/ijc.34296 · 2023 · External reference
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT‐16 Randomized Clinical Trial
10.1001/jama.2023.19918 · 2023 · External reference
Meta‐Analysis of Microsatellite Instability in Relation to Clinicopathological Characteristics and Overall Survival in Gastric Cancer
10.1002/bjs.10663 · 2018 · External reference
Clinicopathological Features and Prognostic Value of Mismatch Repair Protein Deficiency in Gastric Cancer
2018 · External reference
PD‐1 Blockade in Mismatch Repair‐Deficient, Locally Advanced Rectal Cancer
10.1056/nejmoa2201445 · 2022 · External reference
Neoadjuvant PD‐1 Blockade With Toripalimab, With or Without Celecoxib, in Mismatch Repair‐Deficient or Microsatellite Instability‐High, Locally Advanced, Colorectal Cancer (PICC): A Single‐Centre, Parallel‐Group, Non‐Comparative, Randomised, Phase 2 Trial
10.1016/s2468-1253(21)00348-4 · 2022 · External reference
Neoadjuvant Immunotherapy Leads to Pathological Responses in MMR‐Proficient and MMR‐Deficient Early‐Stage Colon Cancers
10.1038/s41591-020-0805-8 · 2020 · External reference
